Table 1. Patient and disease characteristics.

Characteristics	ROS1, n=26	ALK, n=42	P value
Age, years, median at diagnosis of advanced disease [range]	56 [36–82]	56 [36–82]
Sex, n [%]
Male/female	10 [38]/16 [62]	19 [45]/23 [55]	0.583
Smoking history, n [%]
Never/light (<10 pack years)/heavy (≥10 pack years)	15 [58]/5 [19]/6 [23]	26 [62]/5 [12]/11 [26]	0.706
Histopathology, n [%]
Adenocarcinoma/others	23 [88]/3 [12]	42 [100]/0 [0]	0.052
Stage at diagnosis, n [%]
IIIa–IV/recurrence	20 [77]/6 [23]	30 [71]/12 [29]	0.618
ECOG performance states, n [%]
0–1/≥2	24 [92]/2 [8]	37 [88]/5 [12]	0.618
Brain metastasis at diagnosis, n [%]
Present/absent	3 [12]/23 [88]	12 [29]/30 [71]	0.100
Crizotinib treatment line, n [%]
1/2/≥3	10 [38]/6 [23]/10 [38]	23 [55]/11 [26]/8 [19]	0.199

^a, 5 patients in ROS1-positive NSCLC and 2 patients in ALK-positive NSCLC. ECOG, Eastern Cooperative Oncology Group.